CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.

Follow along for the latest news on the major headlines of the day.

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.